Adjuvant anti-PD1 immunotherapy of resected skin melanoma: an example of non-personalized medicine with no overall survival benefit
-
Published:2024-10
Issue:
Volume:202
Page:104443
-
ISSN:1040-8428
-
Container-title:Critical Reviews in Oncology/Hematology
-
language:en
-
Short-container-title:Critical Reviews in Oncology/Hematology
Author:
Ochenduszko SebastianORCID,
Puskulluoglu Miroslawa,
Pacholczak-Madej Renata,
Ruiz-Millo Oreto
Reference68 articles.
1. Back to the future: in the era of cost-effectiveness analysis, affordability is a limiting factor for patients’ access to innovative cancer treatments;Aguiar;Value Heal Reg. Issues,2019
2. Adjuvant nivolumab versus ipilimumab in resected stage IIIB–C and stage IV melanoma (CheckMate 238): 4-year results from a multicentre, double-blind, randomised, controlled, phase 3 trial;Ascierto;Lancet Oncol.,2020
3. 1089P Adjuvant nivolumab (NIVO) vs ipilimumab (IPI) in resected stage III/IV melanoma: 7-y results from CheckMate 238;Ascierto;Ann. Oncol.,2023
4. Dabrafenib plus trametinib versus anti-PD-1 monotherapy as adjuvant therapy in BRAF V600-mutant stage III melanoma after definitive surgery: a multicenter, retrospective cohort study;Bai;EClinicalMedicine,2023
5. Cost-effectiveness of pembrolizumab for the adjuvant treatment of resected high-risk stage III melanoma in the United States;Bensimon;J. Med Econ.,2019